SANO V PTE. LTD.

Sano V is a pioneering men's health medical device company focused on developing innovative vascular solutions for erectile dysfunction. Our breakthrough flow-limiting vascular implant technology addresses venous leakage, a common cause of ED, restoring confidence and quality of life for men worldwide. Founded in Singapore in 2012, Sano V was one of the first promising startups to receive investment under Singapore's $40 million Biomedical Sciences Accelerator (BSA) programme. As part of a select group of high-potential medtech companies, we received early funding from SPRING SEEDS Capital Pte Ltd (SSC), a wholly-owned subsidiary of SPRING Singapore (now Enterprise Singapore). Our team has developed a novel, minimally invasive solution backed by robust clinical research and protected by multiple patents. Our technology has successfully progressed from concept to First-in-man clinical trials in New Zealand and Israel. We are dedicated to addressing the unmet needs in men's health through technological innovation and clinical excellence. By combining medical expertise with engineering precision, we aim to transform treatment options for erectile dysfunction and improve patient outcomes globally. With distributed teams across Singapore, Israel and the United States, Sano V leverages international expertise to develop world-class medical solutions while maintaining the highest standards of quality and regulatory compliance.